The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Go Back to All Clinical Trials

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Brief description of study

This is a randomised, multicentre, double-blinded, parallel-group trial comparing semaglutide s.c. 2.4 mg once-weekly versus placebo in subjects with NASH and fibrosis stage 2 or 3. The trial has two parts, a part 1 and a part 2, with distinctive objectives and endpoints. Part 1 of the trial: To demonstrate that treatment with semaglutide s.c. 2.4 mg improves liver histology compared to placebo in subjects with NASH and fibrosis stage 2 or 3. Part 2 of the trial: To demonstrate that treatment with semaglutide s.c. 2.4 mg lowers the risk of liver-related clinical events compared to placebo in subjects with NASH and fibrosis stage 2 or 3.

Clinical Study Identifier: s20-01271

ClinicalTrials.gov Identifier: NCT04822181

Principal Investigator: Ira M. Jacobson.

Other Investigators: Monique Julia Carasso, Ilyse Haberman, David Fixler, Flordelis Cruz Reyes, Nina M Gardner.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies